Search clinical trials for: AM3

Total 1338 results

University of Illinois at Chicago
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

Cortical Priming to Optimize Gait Rehabilitation Post Stroke

Stroke

United States
Boehringer Ingelheim

Completed

Phase I Dose Escalation of i.v. BI 836909 Monotherapy in Last Line Multiple Myeloma Patients

Multiple Myeloma

Germany, France
Cytokinetics

Withdrawn

Pharmacokinetic Study of Omecamtiv Mecarbil in Heart Failure Patients

Heart Failure
Athersys, Inc
National Heart, Lung, and Blood Institute (NHLBI)

Terminated

A Phase 2 Trial of AMI MultiStem® Therapy in Subjects With Non-ST Elevation Acute Myocardial Infarction (MI-NSTEMI)

Heart Attack | NSTEMI

United States
Amgen

Completed

Abrilumab (AMG 181) in Adults With Moderate to Severe Ulcerative Colitis

Ulcerative Colitis

United States, Belgium, Canada, Denmark, Italy, Hungary, Germany, Switzerland, Netherlands, Australia, Russian Federation, Austria, France, United Kingdom, Czechia, Greece, Poland, Estonia, Latvia, Norway
Amgen

Completed

Abrilumab (AMG 181) in Adults With Moderate to Severe Crohn's Disease

Crohn's Disease

United States, Canada, Denmark, Belgium, Hungary, Switzerland, Netherlands, Austria, Czechia, France, United Kingdom, Germany
Retina Implant AG

Terminated

Impact on Daily Life of Patients Using the Subretinal Implant RETINA IMPLANT Alpha AMS

Retinal Degeneration | Inherited Retinal Dystrophy Primarily Involving Sensory Retina

France
Amgen

Completed

Evaluating the Safety of Long Term Dosing of Romiplostim (Formerly AMG 531) in Thrombocytopenic Subjects With Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes | Thrombocytopenia | MDS | Hematology
Amgen

Completed

Safety and Efficacy Study of Romiplostim (AMG 531) to Treat ITP in Pediatric Subjects

Idiopathic Thrombocytopenic Purpura | Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) | Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Amgen

Completed

Open Label Extension Study of Romiplostim (AMG 531) in Thrombocytopenic Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

Thrombocytopenia | Idiopathic Thrombocytopenic Purpura
Amgen

Completed

A Randomized, Double-blind, Placebo-controlled, Dose Response Study of AMG 162 (Denosumab) in Japanese Postmenopausal Osteoporotic Subjects

Osteoporosis
Amgen

Active, not recruiting

AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)

Small Cell Lung Cancer

United States, Belgium, Austria, Singapore, Taiwan, Japan
Bausch Health Americas, Inc.

Terminated

AMG 827 in Subjects With Psoriatic Arthritis

Psoriatic Arthritis

United States, Canada
Regina Elena Cancer Institute

Recruiting

Versatile Ampification Single-Molecule Detection in Liquid Biopsy (VerSiLiB)

Melanoma (Skin) | Liquid Biopsy | Melanoma Stage IV | Melanoma Stage III | BRAF V600E

Italy
AstraZeneca
Parexel

Recruiting

Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Severe Asthma in the United States (PASSAGE)

Asthma

United States
Applied Molecular Transport

Active, not recruiting

Study of the Efficacy and Safety of AMT-101 in Subjects With Ulcerative Colitis (LOMBARD)

Ulcerative Colitis

United States, Hungary, Ukraine, Germany, United Kingdom, Belarus, Bulgaria, Canada, France, Georgia, Moldova, Republic of, Poland, Russian Federation, Switzerland
Amgen

Completed

Double-blind, Multiple Dose Study of Tezepelumab (AMG 157) in Adults With Mild Atopic Asthma

Asthma

Canada
Amgen

Completed

Safety Study of Tezepelumab (AMG 157) in Healthy Adults and Adults With Atopic Dermatitis

Healthy Volunteers | Atopic Dermatitis
Cytokinetics

Completed

Pharmacokinetics and Safety Study of Omecamtiv Mecarbil in Healthy Japanese Adults

Healthy Volunteer

Japan
Amgen
MedImmune LLC

Terminated

A Phase 1 Study of AMG 211 in Participants With Advanced Gastrointestinal Cancer

GI Adenocarcinoma

Germany, Netherlands
Pfizer

Terminated

A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors

Metastatic Pancreatic Adenocarcinoma | BRAF Mutated Melanoma

United States, Australia, Belgium, Canada, France, Italy, Spain, United Kingdom
Amgen

Completed

Evaluating the Safety and Efficacy of Romiplostim (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)

Idiopathic Thrombocytopenic Purpura
Amgen

Completed

Determination of Safe Dose of Romiplostim (AMG 531) in Patients With Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes | Thrombocytopenia | MDS | Refractory Cytopenias
ALK-Abelló A/S

Completed

Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05233)(COMPLETED)

Conjunctivitis | Rhinitis; Allergic, With Asthma
Amgen

Completed

Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study

Cardiovascular Disease

United States, Australia, Netherlands, Canada, Denmark, Iceland, Japan
Zoll Medical Corporation

Completed

Mobile Cardiac Telemetry and Advanced Multi-Parameter Monitoring in PatientS Wearing a Novel Device With Biometric Based Medications Changes (MAPS II)

Cardiac Arrhythmia

United States
Amgen

Completed

Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim

Idiopathic Thrombocytopenic Purpura

Italy, United States, Germany, Czechia, United Kingdom, Australia, Spain, Poland, France
Notal Vision Ltd.

Completed

HOme Vision Monitoring in AREDS2 for Progression to Neovascular AMD Using the ForeseeHome Device (AREDS)

Age Related Macular Degeneration

United States
Wills Eye
Retina Implant AG

Withdrawn

RETINA IMPLANT Alpha AMS in Blind Patients With Retinitis Pigmentosa

Retinitis Pigmentosa

United States
MedImmune LLC
Amgen

Completed

A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome

Primary Sjögren's Syndrome

United States, Sweden, France, United Kingdom
GlaxoSmithKline

Completed

Relative Bioavailability Study of Marketed and Lower Dose Ambrisentan in Healthy Adult Participants

Hypertension, Pulmonary

United Kingdom
Amgen

Recruiting

A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe AD (ROCKET-Outpost)

Atopic Dermatitis

United States, Canada
uniQure France SAS

Recruiting

AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy

Mesial Temporal Lobe Epilepsy

United States
ART Fertility Clinics LLC

Not yet recruiting

Is Decreased Ovarian Reserve Related to an Increased Number of Previous Early Miscarriages?

Miscarriage, Recurrent | Miscarriage | Infertility, Female | IVF

United Arab Emirates
Amgen

Recruiting

Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis

United States, Taiwan, Germany, Spain, Turkey, Greece, Japan, Switzerland, Denmark, Korea, Republic of, Austria, Italy, Netherlands, Poland, Romania, Belgium, Argentina, Bulgaria, Czechia, Finland, Hungary, Mexico, Latvia, France, Canada, Slovaki...
Boston Scientific Corporation

Completed

Artificial Urinary Sphincter Clinical Outcomes (AUSCO)

Stress Urinary Incontinence

United States, Australia
Amgen

Completed

Study of Romosozumab (AMG 785) Administered to Healthy Participants and Patients With Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemodialysis

Osteoporosis

United States
Amgen

Terminated

Safety and Efficacy of Efavaleukin Alfa in Subjects With Active Rheumatoid Arthritis

Rheumatoid Arthritis RA

United States, Poland, Germany, Bulgaria, Spain
Al Baraka Fertility Hospital

Unknown

AMH and Pregnancy Outcome in IVF

AMH
Lucy A Wibbenmeyer
Medtronic - MITG

Completed

Kerlix Gauze Study in a Burn Trauma Unit and Its Effect on Healthcare Associated Infections in Burn Patients

Burns | Wounds

United States
Universidad Autonoma de Ciudad Juarez

Completed

Physiological Effect of Ataulfo Mango (Manguifera Indica) Beverage in Exercise

Exercise-induced Oxidative Stress
Amgen

Terminated

Study to Evaluate the Safety and Tolerability of AMG 986 in Healthy Volunteers and Heart Failure Patients

Heart Failure | Healthy Volunteer

France, United States, Netherlands, New Zealand, Germany, Australia, Poland, Canada, Singapore
Hannover Medical School
Corscience, Inc.

Completed

Telecommunication Via Cell Phones During Post-Operative Treatment After Lung Transplantation (TeleTx)

Lung Transplantation

Germany
University of Pittsburgh
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Active, not recruiting

PRenatal Video-Based Education and PostPARtum Effects (PREPARE)

Breastfeeding

United States
Amgen

Completed

A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Romosozumab (AMG 785)

Osteopenia | Postmenopausal
AmMax Bio, Inc.

Completed

A Study of AMG 820 in Subjects With Advanced Solid Tumors

Cancer | Advanced Solid Tumors | Oncology | Tumors | Advanced Malignancy | Oncology Patients

United States
PETHEMA Foundation

Completed

VILMA: Therapeutic Results in Acute Mieloblastic Leukemia in Patients Older Than 60 Years

AML

Spain
Amgen

Completed

A Study to Evaluate the Effect of Romosozumab (AMG 785) on Bone Quality of the Forearm in Postmenopausal Women With Low Bone Mass

Osteopenia
Amgen

Completed

A Study to Compare the Safety and Efficacy of Romosozumab (AMG 785) Versus Placebo in Men With Osteoporosis (BRIDGE)

Osteoporosis in Men

United States, Belgium, Colombia, Czechia, Denmark, Japan, Mexico, Poland, Russian Federation, Switzerland
Amyndas Pharmaceuticals S.A.

Completed

First-In-Human Clinical Study of the C3 Complement Inhibitor AMY- 101 in Healthy Male Volunteers

Complement Mediated Diseases

United States

Search clinical trials for: AM3

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kazakhstan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations